Funded Clinical Trials

Explore Our Trials

Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.

Results 41-50 of 56

Pediatric Blood Cancer

Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD

Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD Summary: Allogeneic hematopoietic stem cell transplants (stem cell transplant from a donor) [HSCT] are an important treatment for high-risk hematologic (blood) malignancies. However, these transplants can result in graft versus host disease (GVHD) which targets the skin, liver, and GI tract. This occurs in about […]

John Levine, MD, MS

Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute

Pediatric Blood Cancer

A Phase I and Expansion Cohort Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia

A Phase I and Expansion Cohort Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia Summary: Survival rates for children with AML are greater than 60%; however, the outcome for patients with relapsed or refractory disease remains poor with less than 40% becoming long term […]

Jeffrey Rubnitz, MD, PhD

St. Jude Children's Research Hospital

Pediatric Brain Cancer

Exploiting Mutant IDH1/2-induced DNA Repair Defects in Pediatric Glioma to improve outcomes

Exploiting Mutant IDH1/2-induced DNA Repair Defects in Pediatric Glioma to improve outcomes Summary: Pediatric gliomas are the most commonly encountered tumor types in children and also contribute to the most cancer related deaths in children. There is an urgent need for high-grade gliomas which lack any meaningful standard of care. IDH1/2 gene mutations are common […]

Sabine Mueller, MD, PhD

University of California, San Francisco

Pediatric Blood Cancer

A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative

A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative Summary: Total body irradiation (TBI) in hematopoietic stem cell transplant (HSCT) has been a key element […]

Hisham Abdel-Azim, MD, MS

Children's Hospital Los Angeles

Pediatric Blood Cancer

The safety and tolerability of intravenous fish oil lipid emulsion in children undergoing hematopoietic cell transplantation

The safety and tolerability of intravenous fish oil lipid emulsion in children undergoing hematopoietic cell transplantation Summary: Hematopoietic Stem cell transplant (HSCT) is a potentially life-saving treatment for many patients with blood cancers and is generally the preferred approach for children with a high risk of relapsed disease. However, HSCT is associated with significant toxicity […]

Alexandra Carey, MD

Boston Children's Hospital

Solid Tumors

Fecal microbiota transplantation (FMT) treatment for immune checkpoint inhibitor–mediated colitis

Fecal microbiota transplantation (FMT) treatment for immune checkpoint inhibitor–mediated colitis Summary: Immune checkpoint inhibitors (ICIs) have become paradigm-shifting therapies for a variety of cancers. However, these agents are associated with various toxicities that affect the skin, GI tract, liver, lungs, endocrine system, and nervous system. Immune-mediated colitis (IMC) is among the most encountered severe toxicities […]

Yinghong Wang, MD, PhD

MD Anderson Cancer Center

Breast Cancer

Identification of Predictive Protein Pathway Activation Biomarkers for Neoadjuvant Breast Cancer Therapy Treatment from the ISPY2 TRIAL

Identification of Predictive Protein Pathway Activation Biomarkers for Neoadjuvant Breast Cancer Therapy Treatment from the ISPY2 TRIAL Summary: Over 200,000 women are diagnosed with breast cancer annually in the United States and breast cancer is responsible for approximately 45,000 deaths annually in the U.S. While those diagnosed with early-stage breast cancer have excellent outcomes, 10-20% […]

Emanuel Petricoin, PhD

George Mason University

Breast Cancer

Copper depletion as a therapeutic strategy to prevent metastases in triple negative breast cancer: Unraveling the mechanisms behind the effect of copper depletion on the tumor and tumor microenvironment

Copper depletion as a therapeutic strategy to prevent metastases in triple negative breast cancer: Unraveling the mechanisms behind the effect of copper depletion on the tumor and tumor microenvironment Summary: Triple-negative breast cancer (TNBC) is an aggressive cancer that accounts for 15-20% of all breast cancer cases; however, it is responsible for 50% of metastasis-related […]

Linda Vahdat, MD, MBA

Dartmouth

Breast Cancer

Immune Effects of Sacituzumab Govitecan with or without Pembrolizumab in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer

Immune Effects of Sacituzumab Govitecan with or without Pembrolizumab in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer Summary: Worldwide, breast cancer is the most common non-skin cancer and the leading cause of cancer death in women. In the United States, breast cancer accounts for nearly one-third of all new cancer diagnoses among women with over 250,000 […]

Sara Tolaney, MD, MPH

Dana-Farber Cancer Institute

Pediatric Sarcoma

Phase 2 Study of Regorafenib in Combination with Immune Checkpoint Inhibitor Nivolumab in Patients with Refractory or Recurrent Osteosarcoma

Phase 2 Study of Regorafenib in Combination with Immune Checkpoint Inhibitor Nivolumab in Patients with Refractory or Recurrent Osteosarcoma Summary: Osteosarcoma is the most common malignant bone tumor in children and young adults, with a peak incidence between 13 and 16 years of age. The mainstay of treatment is intensive multi-agent cytotoxic chemotherapy but despite […]

Fariba Navid, MD

Children's Hospital Los Angeles